Debora Giunti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2717137/publications.pdf

Version: 2024-02-01

24 papers 4,374 citations

16 h-index 677142 22 g-index

25 all docs

 $\begin{array}{c} 25 \\ \text{docs citations} \end{array}$

25 times ranked

6080 citing authors

#	Article	IF	CITATIONS
1	Role of miRNAs shuttled by mesenchymal stem cell-derived small extracellular vesicles in modulating neuroinflammation. Scientific Reports, 2021, 11, 1740.	3.3	69
2	A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band. Journal of Neurology, 2017, 264, 973-978.	3.6	18
3	Cerebrospinal fluid analysis and the determination of oligoclonal bands. Neurological Sciences, 2017, 38, 217-224.	1.9	30
4	Can we switch microglia's phenotype to foster neuroprotection? Focus on multiple sclerosis. Immunology, 2014, 141, 328-339.	4.4	67
5	Monomethyl fumarate inhibits the NFkB pathway and pro-inflammatory cytokine expression in microglia through HCA2 signaling via the AMPK/Sirt axis. Journal of Neuroimmunology, 2014, 275, 167-168.	2.3	2
6	Possible role of miRNAs in the modulation of neuroinflammation by mesenchymal stem cells. Journal of Neuroimmunology, 2014, 275, 150.	2.3	0
7	Intravenous Mesenchymal Stem Cells Improve Survival and Motor Function in Experimental Amyotrophic Lateral Sclerosis. Molecular Medicine, 2012, 18, 794-804.	4.4	135
8	Mesenchymal Stem Cells Shape Microglia Effector Functions Through the Release of CX3CL1. Stem Cells, 2012, 30, 2044-2053.	3.2	127
9	Neuroprotective features of mesenchymal stem cells. Best Practice and Research in Clinical Haematology, 2011, 24, 59-64.	1.7	195
10	Systemic Administration of Mesenchymal Stem Cells Increases Neuron Survival after Global Cerebral Ischemia In Vivo (2VO). Neural Plasticity, 2010, 2010, 1-5.	2.2	24
11	Human mesenchymal stem cells modulate B-cell functions. Blood, 2006, 107, 367-372.	1.4	1,583
12	Mechanisms of the adaptive immune response inside the central nervous system during inflammatory and autoimmune diseases., 2006, 111, 555-566.		30
13	Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood, 2005, 106, 1755-1761.	1.4	1,318
14	Consensus recommendations of the Italian Association for Neuroimmunology for immunochemical cerebrospinal fluid examination. Journal of the Neurological Sciences, 2005, 237, 5-11.	0.6	13
15	Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 11064-11069.	7.1	322
16	\hat{l}_{\pm} -Lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2004, 148, 146-153.	2.3	118
17	Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS. Journal of Leukocyte Biology, 2003, 73, 584-590.	3.3	159
18	Demyelination and axonal damage in a non-human primate model of multiple sclerosis. Journal of the Neurological Sciences, 2001, 184, 41-49.	0.6	74

#	Article	IF	CITATION
19	Central and peripheral nervous system complications following allogeneic bone marrow transplantation. European Journal of Neurology, 2001, 8, 77-80.	3.3	37
20	Characterization of the response to myelin basic protein in a non human primate model for multiple sclerosis. European Journal of Immunology, 2001, 31, 474-479.	2.9	9
21	Restricted immune responses lead to CNS demyelination and axonal damage. Journal of Neuroimmunology, 2000, 107, 178-183.	2.3	11
22	Myelin basic protein intramolecular spreading without disease progression in a patient with multiple sclerosis. Journal of Neuroimmunology, 2000, 110, 240-243.	2.3	12
23	A major influence of the T cell receptor repertoire as compared to antigen processing–presentation in the selection of myelin basic protein epitopes in multiple sclerosis. Journal of Neuroimmunology, 1999, 96, 241-244.	2.3	1
24	A restricted T cell response to myelin basic protein (MBP) is stable in multiple sclerosis (MS) patients. Clinical and Experimental Immunology, 1998, 111, 186-192.	2.6	18